Product Images Losortan Potassium

This is a summary of a study showing the comparison of the effectiveness of Atenolol and Losartan Potassium in reducing the risk of the primary endpoint. Atenolol showed a risk reduction of 13% compared to Losartan Potassium. The study was conducted over a period of 66 months with measurements taken at various intervals.*

This is a chart showing the percentage of patients who experienced either fatal or non-fatal stroke while taking Atenolol or Losartan Potassium. The chart displays adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001. The study was conducted over a period of 66 months.*

This appears to be a table or graph showing the percentage of patients with an event and the risk reduction for Losartan Potassium tablets compared to a placebo. The table also shows a significant p-value of 0.022. However, without more context, it is difficult to provide a more detailed description or interpretation of the results.*

This is a medication label for Losartan Potassium tablets, USP typically used for treating high blood pressure. Each bottle contains 30 tablets and has an NDC number of 68382-135-06. The dosage and usage instructions are not provided in the given text.*

This is a description of a medication named "Potassium Tablets, USP". The format and presentation of the text is not clear. The medication is manufactured by "Zydus Ronty B" company and is available in 30 tablet form.*

Losartan and Potassium Tablets, USP are a medication produced by Pramacautiss in the USA. Unfortunately, the text is fragmented and incomplete, making it difficult to provide any additional useful information.*